KP-1077 is under clinical development by Zevra Therapeutics and currently in Phase II for Idiopathic Hypersomnia (IH). According to GlobalData, Phase II drugs for Idiopathic Hypersomnia (IH) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KP-1077’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KP-1077 overview
Zevra Therapeutics overview
Zevra Therapeutics (Zevra) is a therapeutics company that specializes in the development of drugs for rare diseases. The company’s main activities focuses on the use of creative, data-driven strategies to overcome complex drug development and regulatory challenges. Its products include AZSTARYS, a federally controlled substance used for therapeutic purposes; OLPRUVA, used for certain urea cycle disorders. Zevra’s pipeline products include Arimoclomol, Celiprolol, and KP1077. The company operates in the US. Zevra is headquartered in Florida, the US.
For a complete picture of KP-1077’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
